Fifty 410 review: November 2026 prices, terms and what to verify
As of November 20, 2026, Fifty 410’s own page lists tirzepatide $199 per 4-week program or $299 per 8-week program (not in all states); semaglutide $199 per 4-week program. On this site’s computed price-and-transparency score it has 23.5 of 40 points, position 8 of 27 compounded programs.
Released · Last reviewed · how we verify
What Fifty 410 charges now
Fifty 410’s prices were read on its own page on November 20, 2026 (changed since the last read). This site compares programs on the all-in month-to-month price at the maintenance dose, which counts any required membership or program fee and leaves out first-month offers. A 28-day billing cycle means 13 charges a year, not 12.
| Medication | Month to month, all-in | Billing basis | Lowest printed rate | Year at month-to-month price | Read |
|---|---|---|---|---|---|
| Compounded tirzepatide | $199 | per 28-day cycle | $149.50 (8-week program at $299, not in all states) | $2,587 (13 four-week cycles) | 2026-11-20 |
| Compounded semaglutide | $199 | per 28-day cycle | $199 (4-week program) | $2,587 (13 four-week cycles) | 2026-11-20 |
Fifty 410 on the computed score
On this site’s computed price-and-transparency score it has 23.5 of 40 points, position 8 of 27 compounded programs. The score covers the two parts of our seven-category methodology that can be checked for every program on the same day: pricing transparency (20 points) and total annual cost (20 points). The full ranking is on the rankings page.
| Check | Tirzepatide | Semaglutide |
|---|---|---|
| prints a month-to-month price | yes (+4) | yes (+4) |
| medication and care in one price | yes (+4) | yes (+4) |
| same price at every dose | no (0) | no (0) |
| no membership fee | yes (+4) | yes (+4) |
| price read on its own page on November 20, 2026 | yes (+4) | yes (+4) |
| Year at the month-to-month price | $2,587 | $2,587 |
| Total annual cost points | 7.9 of 20 | 7 of 20 |
| Score for this drug | 23.9 of 40 | 23 of 40 |
FDA warning letters
FDA’s warning-letter index lists warning letter 721481 (dated February 20, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to Fifty 410; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Limitations: five things to get in writing before you pay
Ask for the all-in price at your current dose and at the maintenance dose; the amount charged today and whether it recurs monthly or is prepaid; the licensed pharmacy that fills the prescription; the cancellation and refund terms, word for word; and what happens to your price when the dose goes up. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy.
Frequently asked
Does Fifty 410 charge a membership fee?
No required membership fee appeared on Fifty 410’s page when it was read on November 20, 2026; the figures above are the full recurring charge before tax.
Does Fifty 410 take insurance?
Not for compounded medication. Fifty 410 is a cash-pay program in this dataset (August 2026 capture), and insurers do not cover compounded GLP-1s. If your plan covers Zepbound or Wegovy, check that first, because a covered brand prescription usually costs less than any cash price.
Which states does Fifty 410 serve?
Fifty 410’s published coverage in the August 2026 capture was: not published. Telehealth prescribing depends on state licensing and changes often, so confirm your state at the start of the intake. The state pages list what each program publishes.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Fifty 410 pricing page (read November 20, 2026)
- Fifty 410 semaglutide page (read November 20, 2026)
- FDA warning letter 721481 to Fifty 410 (dated 2026-02-20, posted 2026-03-03; read November 20, 2026)